Adherence, persistence and efficacy of dasatinib and nilotinib in the treatment of patients resistant or intolerant to imatinib with chronic myeloid leukemia in chronic phase: an Italian multicenter study over two years in real life

Santoleri Fiorenzo; Ranucci Elena; La Barba Gaetano; Colasanto Irene; Scaldaferri Matilde; Cattel Francesco; Federici Francesca; Rossi Chiara; Di Biagio Katiuscia; Scortechini Anna Rita; Musicco Felice; Torquati Giancarlo; Frazzetto Angela; Vozza Antonietta; de Rosa Caterina; Lanzillo Rosaria; Monteverde Maria; Luciano Luigia; Pane Fabrizio; Pasquazi Arianna; Celeste Maria Grazia; Cantonetti Maria; Franceschini Luca; Rizzo Manuela; Costantini Alberto

首页> 外文期刊>Current medical research and opinion >Adherence, persistence and efficacy of dasatinib and nilotinib in the treatment of patients resistant or intolerant to imatinib with chronic myeloid leukemia in chronic phase: an Italian multicenter study over two years in real life

【24h】

Adherence, persistence and efficacy of dasatinib and nilotinib in the treatment of patients resistant or intolerant to imatinib with chronic myeloid leukemia in chronic phase: an Italian multicenter study over two years in real life

机译：达沙替尼和尼洛涅布在治疗耐药性或慢性骨髓白血病患者治疗患者的粘附，持续和疗效，慢性阶段慢性骨髓白血病：在现实生活中两年内的意大利多中心研究

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background

机译：None

著录项

来源
《Current medical research and opinion》 |2021年第3期|共5页
作者
Santoleri Fiorenzo; Ranucci Elena; La Barba Gaetano; Colasanto Irene; Scaldaferri Matilde; Cattel Francesco; Federici Francesca; Rossi Chiara; Di Biagio Katiuscia; Scortechini Anna Rita; Musicco Felice; Torquati Giancarlo; Frazzetto Angela; Vozza Antonietta; de Rosa Caterina; Lanzillo Rosaria; Monteverde Maria; Luciano Luigia; Pane Fabrizio; Pasquazi Arianna; Celeste Maria Grazia; Cantonetti Maria; Franceschini Luca; Rizzo Manuela; Costantini Alberto;
展开▼
作者单位

Pescara Gen Hosp Pescara Italy;

Pescara Gen Hosp Hematol Oncol Dept Via R Paolini 47 I-65124 Pescara Italy;

Pescara Gen Hosp Hematol Oncol Dept Via R Paolini 47 I-65124 Pescara Italy;

Azienda Osped Univ Citta Salute &

Sci Torino Turin Italy;

Azienda Osped Univ Citta Salute &

Sci Torino Turin Italy;

Azienda Osped Univ Citta Salute &

Sci Torino Turin Italy;

ASUR Marche Ancona Italy;

ASUR Marche Ancona Italy;

Reg Environm Protect Agcy Marche Environm Epidemiol Unit Ancona Italy;

Azienda Osped Univ Osped Riuniti Hematol Unit Ancona Italy;

Regina Elena San Gallicano Canc &

Dermatol Inst Rome Italy;

Regina Elena San Gallicano Canc &

Dermatol Inst Rome Italy;

Regina Elena San Gallicano Canc &

Dermatol Inst Rome Italy;

Azienda Osped Univ Federico II Naples Italy;

Azienda Osped Univ Federico II Naples Italy;

Azienda Osped Univ Federico II Naples Italy;

Univ Naples Federico II Med Sch Dept Clin Med &

Surg Naples Italy;

Univ Naples Federico II Med Sch Dept Clin Med &

Surg Naples Italy;

Univ Naples Federico II Med Sch Dept Clin Med &

Surg Naples Italy;

Policlin Tor Vergata PTV Fdn Rome Italy;

Policlin Tor Vergata PTV Fdn Rome Italy;

Policlin Tor Vergata PTV Fdn Unit Lymphoproliferat Disorders Rome Italy;

Policlin Tor Vergata PTV Fdn Unit Lymphoproliferat Disorders Rome Italy;

Policlin Tor Vergata PTV Fdn Unit Lymphoproliferat Disorders Rome Italy;

Pescara Gen Hosp Pescara Italy;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类医药、卫生;
关键词
Dasatinib; nilotinib; drug used study; medication adherence; persistence; effectiveness; chronic myeloid leukaemia;

机译：Dasatinib;尼洛尼布;药物使用的研究;药物依恋;持续存在;有效性;慢性骨髓白血病;

相似文献

外文文献
中文文献
专利

1. Efficacy and Safety of Generic Dasatinib as a Second-line Treatment for Patients with Chronic Myeloid Leukemia:a Multicenter Retrospective Study in Hubei Province,China [J] . Li-feng CHEN, Guo-lin YUAN, Zhao-dong ZHONG, 当代医学科学(英文) . 2018,第006期
2. The combination therapy of imatinib and dasatinib achieves long-term molecular response in two imatinib-resistant and dasatinibintolerant patients with advanced chronic myeloid leukemia [J] . Yu Zhu, Liangqin Pan, Ming Hong, 生物医学研究杂志（英文版） . 2016,第006期
3. The combination therapy of imatinib and dasatinib achieves long-term molecular response in two imatinib-resistant and dasatinibintolerant patients with advanced chronic myeloid leukemia [J] . Yu Zhu, Liangqin Pan, Ming Hong, 生物医学研究杂志：英文版 . 2016,第006期
4. Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients† [J] . Giuseppe Visani, Massimo Breccia, Antonella Gozzini, AMERICAN JOURNAL OF HEMATOLOGY . 2010,第12期

机译：达沙替尼，即使是低剂量的，也是对伊马替尼耐药或不耐受的慢性粒细胞白血病患者的有效二线治疗。一项基于现实生活的意大利多中心回顾性研究对114例患者的结果†
5. Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients. [J] . Visani G, Breccia M, Gozzini A, American Journal of Hematology . 2010,第12期

机译：达沙替尼，即使是低剂量的，也是对伊马替尼耐药或不耐受的慢性髓性白血病患者的有效二线治疗。来自对114名患者进行的基于现实生活的意大利多中心回顾性研究的结果。
6. Multicenter phase II clinical trial of nilotinib for patients with imatinib-resistant or -intolerant chronic myeloid leukemia from the East Japan CML study group evaluation of molecular response and the efficacy and safety of nilotinib [J] . Naoto Takahashi, Masatomo Miura, Jun Kuroki, Biomarker Research . 2014,第1期

机译：尼洛替尼治疗伊马替尼耐药或不耐受的慢性粒细胞白血病的多中心II期临床试验，来自日本东部CML研究组，评估了其分子响应以及尼洛替尼的疗效和安全性
7. Efficiency and Toxmcity of the Fludarabine and Cyclo- Phosphamide Combined Therapy in Relapsed/ Resistant Patients with B-cell Chronic Lymphocytic Leukaemia (CLL)-Polish Multicenter Study [C] . M. Kowal, A. Dmoszynska, D. Jawniak, European Haematology Association . 2002

机译：B-Cell慢性淋巴细胞白血病（CLL） - 渗透多中心研究的复发/抗性患者复发/抗性患者的氟氮胺碱和环磷酰胺联合治疗的效率和毒性
8. Influences on physician recommendation for imatinib mesylate in chronic phase chronic myeloid leukemia patients. [D] . Iyer, Shrividya Sethuraman. 2003

机译：对慢性期慢性粒细胞白血病患者甲磺酸伊马替尼的医师推荐的影响。
9. Multicenter phase II clinical trial of nilotinib for patients with imatinib-resistant or -intolerant chronic myeloid leukemia from the East Japan CML study group evaluation of molecular response and the efficacy and safety of nilotinib [O] . Naoto Takahashi, Masatomo Miura, Jun Kuroki, 2014

机译：尼洛替尼用于伊马替尼耐药或不耐受的慢性粒细胞白血病的多中心II期临床试验来自日本东部CML研究组评估其分子反应以及尼洛替尼的疗效和安全性
10. Multicenter phase II clinical trial of nilotinib for patients with imatinib-resistant or -intolerant chronic myeloid leukemia from the East Japan CML study group evaluation of molecular response and the efficacy and safety of nilotinib [O] . Naoto Takahashi, Masatomo Miura, Jun Kuroki, 2014

机译：尼洛替尼用于伊马替尼耐药或不耐受的慢性髓性白血病患者的多中心II期临床试验，来自日本东部CML研究组，评估其分子反应以及尼洛替尼的疗效和安全性
11. Report on the Relative Efficacy of Oral Cancer Therapy for Medicare Beneficiaries Versus Currently Covered Therapy: Part 3, Imatinib for Chronic Myeloid Leukemia (CML) [R] . Abernethy, A. P., McCrory, D. C. 2005

机译：报告口服癌疗法对医疗保险受益人与目前报道疗法的相对疗效：第3部分，伊马替尼治疗慢性粒细胞白血病（CmL）

Adherence, persistence and efficacy of dasatinib and nilotinib in the treatment of patients resistant or intolerant to imatinib with chronic myeloid leukemia in chronic phase: an Italian multicenter study over two years in real life

摘要

著录项

相似文献

相关主题

期刊订阅